Latest News

Latest News

ADHD Management for the Entire Active Day is Within Reach

ADHD Management for the Entire Active Day is Within Reach

When you’re a child, leaving an amusement park after a wondrous day is hard. Adults know a similar feeling after a vacation or the finale of a favorite television series. Of course, it’s always disappointing when an enjoyable experience runs out. Still, the stakes are...

read more
Weekly News Roundup | 31 August 2026

Weekly News Roundup | 31 August 2026

Life science news 31 August 2026: three US approvals, two UK device safety alerts and two licensing deals. Revolution Medicines won approval for a broad RAS-targeted pancreatic cancer drug. AstraZeneca and Ionis presented the full data behind a closely watched heart...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Emotion-Aware Companion Robotics: Rethinking Aged Care

Emotion-Aware Companion Robotics: Rethinking Aged Care

Ageing at home is widely accepted as the ideal outcome for older adults, families and healthcare systems, but the way we attempt to support it is deeply flawed. Most technologies deployed into homes today are built on a reactive model of care - where they wait for...

read more
Raising Expectations for Medical Liaisons

Raising Expectations for Medical Liaisons

In the last decade, the Medical Science Liaison role has evolved from a scientific messenger to a field based strategist operating in one of the most highly scrutinized environments in healthcare. That evolution is why board certification is moving from optional...

read more
Emotion-Aware Companion Robotics: Rethinking Aged Care

Emotion-Aware Companion Robotics: Rethinking Aged Care

Ageing at home is widely accepted as the ideal outcome for older adults, families and healthcare systems, but the way we attempt to support it is deeply flawed. Most technologies deployed into homes today are built on a reactive model of care - where they wait for...

read more
Raising Expectations for Medical Liaisons

Raising Expectations for Medical Liaisons

In the last decade, the Medical Science Liaison role has evolved from a scientific messenger to a field based strategist operating in one of the most highly scrutinized environments in healthcare. That evolution is why board certification is moving from optional...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

GSK Makes $2.2 Billion Bid for RAPT Therapeutics

GSK Makes $2.2 Billion Bid for RAPT Therapeutics

GSK has agreed to acquire US biotech company RAPT Therapeutics in a deal valued at approximately 2.2 billion US dollars, strengthening its position in immunology and signalling a major push into the emerging food allergy treatment market. The acquisition centres on...

read more
What is the Metabolic Reset Diet – The Science

What is the Metabolic Reset Diet – The Science

The science, the promise, and the pitfalls The idea of a “metabolic reset” has gained traction across wellness media, social platforms, and weight management programmes. The premise is appealing: that metabolism can be “retrained” or “rebooted” through short-term...

read more
Functional Gut Clinic Launches GI Clinical Trials Division

Functional Gut Clinic Launches GI Clinical Trials Division

The Functional Gut Clinic (FGC), the UK’s leading provider of specialist gastrointestinal (GI) diagnostics, today announced the launch of its dedicated GI Clinical Trials establishing the organisation as the country’s first boutique, end‑to‑end clinical research...

read more

Further News

The NewCo Model: How Big Pharma Spins Out Pipeline Assets

The NewCo model biopharma strategy has rapidly become one of the most consequential dealmaking trends in the life sciences industry. Rather than shelving deprioritised pipeline assets or selling them outright through traditional licensing agreements, major...

Diranersen: First Tau Drug to Show Cognitive Benefit in Alzheimer’s

The first Phase 2 clinical evidence that a tau Alzheimer's drug can simultaneously reduce brain tangles and slow cognitive decline was presented at the Alzheimer's Association International Conference (AAIC) 2026 in London on 14 July. Biogen's diranersen, an antisense...

NAMs and Animal Testing: Separating Progress From Hype

If you followed the headlines over the past two years, you could be forgiven for thinking animal testing in drug development is already on its way out. In December 2022, the FDA Modernization Act 2.0 removed the blanket legal requirement for animal studies to support...

Clinical Trials Roundup | 17 July 2026

Celcuity's gedatolisib receives FDA approval as the first pan-PI3K and mTOR inhibitor for advanced breast cancer, Biogen's diranersen delivers detailed Phase 2 CELIA data showing tau reduction and cognitive benefit in early Alzheimer's disease, Novo Nordisk's...

Biopharma H1 2026 Review: Deals, Drugs, and Pipeline Shifts

The first half of 2026 delivered one of the most consequential periods in recent biopharma history, reshaping competitive landscapes through record dealmaking, landmark regulatory approvals, and pivotal clinical breakthroughs. This biopharma H1 2026 review examines...

AI Can Do More Than Summarize Medicine—It Can Help Generate Evidence

Our healthcare system has built a rigorous process for generating the evidence that clinicians, researchers and pharmaceutical companies rely on. Designing studies, conducting clinical trials, analyzing data, completing regulatory review and publishing results are all...

CagriSema FDA Review: Novo Nordisk NDA Timeline Explained

The CagriSema FDA review has become one of the most closely watched regulatory processes in metabolic medicine. Novo Nordisk filed a New Drug Application for its once-weekly obesity combination in December 2025, and a decision is widely expected in the final quarter...

Life Science Daily News: Eight Months of Growth and a Global Community Taking Shape

Editor’s note: This article reflects our plans and pricing as at July 2026. For current publishing options, see our Join and Publish page. Life Science Daily News launched in November 2025 with a simple premise: that researchers, biotech founders, healthcare...

The Evidence Gap in Precision Prevention

Preventive medicine is entering a new era. Advances in genomics, biomarker testing, continuous monitoring technologies, imaging, and data analytics are enabling clinicians to identify disease risk with a level of precision that would have been unimaginable just a...

Are Animal Models Limiting Progress in Product Development?

While animal models have played a central role in safety assessment and biological research for decades, advances in cellular biology, computational modelling, and micro physiological systems are prompting scientists to explore new ways of generating human-relevant...

Daraxonrasib FDA Filing: What Happens Next for Pancreatic Cancer Patients?

The daraxonrasib FDA filing is nearing completion, marking a pivotal regulatory moment for patients with metastatic pancreatic ductal adenocarcinoma (PDAC). Revolution Medicines announced on 7 July 2026 that its rolling submission of a New Drug Application (NDA) to...

Digital Twin: The Future of Pharmaceutical Manufacturing Science

Pharmaceutical manufacturing is entering a new scientific era. For decades, the industry has relied on validated processes, fixed control strategies, laboratory testing and carefully documented batch records to prove that medicines are made consistently and safely....

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.

See More Articles

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.